Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

In the last decades significant progress has been achieved in the biological understanding of non-small-cell lung cancer (NSCLC) and its tumor heterogeneity has become more evident. The identification of novel tumor targets with different pathways has stimulated the search for anti-tumor agents with...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Transl Lung Cancer Res
Asıl Yazarlar: Pilz, Lothar R, Manegold, Christian, Schmid-Bindert, Gerald
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Pioneer Bioscience Publishing Company 2012
Konular:
Review Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367593/
https://ncbi.nlm.nih.gov/pubmed/25806152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2011.12.08
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller